Post
Carolyn Bertozzi @CarolynBertozzi · Nov 10, 2022
  • From Twitter

Great issue, esp the article by @LImmunotherapy and @AlfredZippelius on immune therapies that target the TME in general and sialoglycan/Siglec axis in particular, some of the more promising candidates in the pipeline. #glycotime @Palleon_Pharma @InterVennBioSci

Recommended by 1 person
1 mention
Share on Twitter Repost
Replies
Reply
No replies yet